Sotagliflozin
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 304 publications
Cardiorenal Safety and Efficacy of Sotagliflozin: A Stratified Meta-Analysis by Diabetes Type and Dosage.
Journal: Diabetes, obesity & metabolism
Published: March 24, 2026
Sotagliflozin Ameliorates LPS‑Induced Cardiomyocyte Injury by Regulating the PI3K‑Akt and Extracellular Matrix-Related Pathways.
Journal: Current gene therapy
Published: February 25, 2026
Comparative clinical outcomes and safety of finerenone, SGLT2 inhibitors, RAS inhibitors and ARNI in heart failure with preserved or mildly reduced ejection fraction: a systematic review and network meta-analysis.
Journal: Frontiers in pharmacology
Published: February 18, 2026
Evaluation of the therapeutic effect of new hypoglycemic drugs on patients with heart failure with reduced ejection fraction and type 2 diabetes: a systematic review and network meta-analysis.
Journal: Frontiers in cardiovascular medicine
Published: January 29, 2026
Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial.
Journal: Circulation. Heart failure
Published: January 22, 2026
Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis.
Journal: Medical sciences (Basel, Switzerland)
Published: January 20, 2026
SGLT1 and SGLT2 Modulation in Antidiabetic Therapy-Comparative Insights into Gliflozins and Natural Compounds Resveratrol and Viniferin.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 11, 2026
Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial.
Journal: Diabetes, obesity & metabolism
Published: December 21, 2025
Sotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: December 18, 2025
Design, Optimization, and Biological Evaluation of First-in-Class Triple Inhibitors of SGLT1, SGLT2, and DPP4 for Type 2 Diabetes Mellitus.
Journal: Journal of medicinal chemistry
Published: December 12, 2025
Targeting Metabolic Dysfunction and Inflammation with Sotagliflozin Reverses Diastolic Dysfunction in Experimental HFpEF.
Journal: bioRxiv : the preprint server for biology
Published: December 11, 2025
Development and bioanalytical validation of a high-sensitivity LC-MS/MS assay for quantitative determination of sotagliflozin in rabbit plasma and its stability across controlled storage conditions.
Journal: BMC chemistry
Published: December 10, 2025
Last Updated: 06/30/2026